Destiny Pharma PLC Destiny Pharma to Join Equity Development Webinar
March 29 2021 - 6:00AM
RNS Non-Regulatory
TIDMDEST
Destiny Pharma PLC
29 March 2021
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Destiny Pharma to Join Equity Development Webinar on
Positive Phase 2b Top-line Results for XF-73 Nasal Gel
Primary endpoint achieved with >99% nasal bacterial load
reduction (p<0.0001)
No treatment related adverse events
Brighton, United Kingdom - 29(th) March 2021 - Destiny Pharma
(AIM: DEST), a clinical stage innovative biotechnology company
focused on the development of novel medicines that can prevent life
threatening infections, announces that the Company's management
team will host a live presentation on Tuesday 30(th) March at
3:30pm BST with Equity Development.
On Monday 29(th) March, the Company was pleased to announce
positive top-line results from its Phase 2b clinical study testing
its XF-73 nasal gel product in patients undergoing surgery at risk
of post-surgical infections such as methicillin-resistant
Staphylococcus aureus (MRSA) . The primary efficacy endpoint was
met and there were no treatment related safety events. Click on the
link to the press release here .
The presentation will be hosted by Neil Clark, Chief Executive
Officer and Shaun Claydon, Chief Financial Officer. The online
presentation is open to all existing and potential shareholders.
Questions can be submitted during the presentation to be addressed
at the end.
To register for the Equity Development webinar please click
here:
https://zoom.us/webinar/register/WN_eIPSQ5KaRYqdy6OIzZZD-A
A recording of the presentation will be available after the
event on both the Equity Development website and on the Destiny
Pharma website.
ENDS
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
DestinyPharma@optimumcomms.com
+44 (0) 203 174 1789
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which is in a Phase 2b clinical trial targeting the prevention of
post-surgical Staphylococcal hospital infections including MRSA. It
is also co-developing SPOR-COV, a novel, biotherapeutic product for
the prevention of COVID-19 and other viral respiratory infections
and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPUUPWUPGUBB
(END) Dow Jones Newswires
March 29, 2021 07:00 ET (11:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024